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TRIOLOGICAL SOCIETY
CANDIDATE THESIS

Biological Significance of Genome-Wide DNA Methylation
Profiles in Keloids
Lamont R. Jones, MD, MBA; Joshua Greene, MD; Kang Mei Chen, MD; George Divine, PhD;
Dhananjay Chitale, MD; Veena Shah, MD; Indrani Datta, MS; Maria J. Worsham, PhD
Objectives/Hypothesis: To obtain biological insight into keloid pathogenesis and treatment using pathway analysis of
genome-wide differentially methylated gene profiles between keloid and normal skin.
Study Design: Prospective cohort.
Methods: Genome-wide profiling was previously done, with institutional review board approval, on six fresh keloid and
six fresh normal skin tissue samples, using the Infinium HumanMethylation450 BeadChip kit. Statistically significant differentially methylated cytosine-phosphodiester bond-guanines (CpGs, n 5 197) between keloid and normal tissue mapped to 152
genes. These genes were uploaded into Ingenuity Pathway Analysis (IPA) software to identify biological functions or regulatory networks interacting. The pathways (or “network”) with an enrichment probability value  .01 were subjected to a heuristic filter of keywords associated with keloid pathogenesis.
Results: Of the 197 CpGs, 191 were found in the IPA database and mapped to 152 unique genes. The top 10 hypermethylated genes were ACTR3C, LRRC61, PAQR4, C1orf109, SLCO2B1, CMKLR1, AHDC1, FYCO1, CCDC34, and CACNB2. The top 10
hypomethylated genes were GALNT3, SCML4, PPP1R13L, ANKRD11, WIPF1, MX2, IFFO1, DENND1C, CFH, and GHDC. IPA identified nine pathways with enrichment probability values  .01, of which five (histidine degradation V1, phospholipase C signaling, colorectal cancer metastasis signaling, P2Y purinergic receptor signaling, and Gai signaling) were associated with keloid
keywords and contained “keloid genes” (P < .05).
Conclusions: Genes differentially methylated between keloid and normal skin reside in known bionetwork pathways
involved in critical biological functioning and signaling events in the cell. This information could be used to refine screening
processes for biological significance to better understand keloid pathogenesis and to develop molecular-targeted therapy.
Key Words: Methylation, epigenetics, keloid, pathway analysis.
Level of Evidence: NA
Laryngoscope, 127:70–78, 2017

INTRODUCTION
Keloids are benign fibroproliferative tumors of the
skin that are more common in darker skinned individuals.1 They usually occur following injury to the dermis,
although spontaneous occurrences have been reported.2
Keloids are fairly common, with >425,000 associated
clinical visits annually in the United Sates3 and as
many as 11 million people affected in the developed
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world.4 Current treatments are disappointing, with
recurrence rates of up to 50% to 100%,1,5–7 mainly due
to incomplete understanding of the pathogenesis of
keloid formation.8 Once thought of mostly as a cosmetic
issue, keloids are often associated with pain, itching,
emotional distress, and loss of function.9
Traditional methods for assessing the pathogenesis
of keloid formation have focused on genetic concepts one
gene at a time.8 Keloid pathogenesis has been attributed
to gene abnormalities important in apoptosis, extracellular matrix formation, and immunity.9,10 Similarly, previous studies have demonstrated irregularities in genes
that both promote and inhibit apoptosis in keloid tissue
such as the upregulation of the tumor-suppressor gene
(TSG) p53 and proto-oncogene bcl2.11 However, no single
gene mutation has been identified. Furthermore, these
traditional methods have failed to account for the complexity of keloids. Similarly, previous multigene analysis
has shown limited ability to completely characterize
keloid pathogenesis and has failed to identify a successful treatment.
Epigenetics, the study of the alteration of gene
expression without changing DNA sequence, is becoming
an alternative to explain gene regulation, and it may
account for the complexity in disease that cannot be
explained with genetic and environmental factors alone.
Jones et al.: DNA Methylation Profiles in Keloids

TABLE I.
Top Canonical Pathways.

Ingenuity Canonical
Pathways

P

No. (Name) of
Differentially Keloid
Methylated Genes/
Total No.
Pathway Genes

Histidine degradation VI

.0017

2 (AMDHD1, MICAL3)/20

Phospholipase C
signaling

.0059

6 (ARHGEF4, AHNAK,
ADCY3, CREB5, GNG4,
PLD1)/260

Colorectal cancer
metastasis
signaling

.0068

6 (TLR1, JAK1, TLR5,
ADCY3, MMP2, GNG4)/
258

P2Y purinergic
receptor
signaling

.0100

4 (ADCY3, P2RY12,
CREB5, GNG4)/138

Gai signaling

.0102

4 (CCR4, ADCY3,
P2RY12, GNG4)/132

This alternative mechanism for regulating genes may
help to fill gaps in knowledge of keloid pathogenesis left
from gene mutation analysis. Methylation is the most
common form of epigenetics, whereby increased methylation (hypermethylation) turns off genes and decreased
methylation (hypomethylation) turns on genes. Methylation is important for both normal and abnormal development. For example, DNA hypermethylation is used to
turn off genes during imprinting in conditions such as
normal X chromosomal inactivation and abnormal conditions such as Prader-Willi syndrome.12–14 Aberrant
hypermethylation or hypomethylation of promoter
methyl groups (CH3) at cytosine bases has been
implicated in the inactivation of TSGs and activation of
proto-oncogenes and subsequent tumorigenesis akin
to gene mutations that can promote tumorigenesis.
This aberrant methylation is the result of DNAmethyltransferases DNMT3A and DNMT3B, mainly in
the cytosine-phosphodiester bond-guanine (CpG) islands
of a gene’s promoter region.15 De novo hypermethylation
of TSGs and subsequent inactivation can lead many cells
down the tumorigenesis continuum.16–18 In many cancers, aberrant CpG island DNA methylation is frequently associated with promoters or first exons,
resulting in anomalous transcriptional silencing of critical genes.19–21 DNA methylation events represent an
early and important tumor-specific marker during
tumorigenesis, detectable by polymerase chain reaction.
Our group has previously characterized the keloid
methylome as more hypomethylated than hypermethylated, using a global discovery approach of the Illumina
(San Diego, CA) 450K bead chip to identify differentially
methylated genes between keloid and normal tissue.8
The identified keloid-specific methylated markers from
that study provided initial insight into the molecular
pathogenesis of keloids from a methylome perspective.
The availability of high-throughput gene analysis platforms has fueled bioinformatic interpretation of large
data sets for further characterization, in the context of
molecular pathways and networks, to establish the relevance of biological processes. The latter presents an
Laryngoscope 127: January 2017

opportunity to further decipher the biological significance of the significantly differentially methylated genes
underpinning the molecular pathogenesis of keloids and
as potential targets for novel treatment of keloids. The
rationale for bionetworks is to move beyond examining
single gene effects to the identification of groups (e.g.,
modules) of genes whose expression is regulated in a
coordinated manner (gene network).12,13 Bionetworks
provide a convenient framework to explore the context
in which single genes operate and represent an exciting
method of discovering important correlations.
This study was undertaken to further understand
the role of DNA methylation in the pathogenesis and
treatment of keloids. Specifically, the study aimed to
demonstrate the use of pathway analysis to identify
gene signaling and regulatory networks to determine
the biological significance of the differentially methylated keloid genes. The biological processes highlighted
by pathway analysis will be used to generate novel
hypotheses for further elucidation of the role of DNA
methylation in keloid pathogenesis and treatment. Furthermore, findings from this study may help to explore
keloids as a potential model for tumorigenesis, because
their clinical characteristics of hyperplasia and recurrence, although mimicking a tumorigenesis continuum,
do not cross the threshold to malignancy.14

MATERIALS AND METHODS
A cohort of six fresh keloid and six fresh normal skin samples was previously obtained using an institutional review
board-approved protocol.8 Genome-wide profiling was previously
done on the cohort using the Infinium HumanMethylation450
BeadChip kit.8 Keloid and normal samples were genotyped for
CpG sites in the Illumina human methylation 450K array and
extracted with the Genome Studio Methylation module.8 There
were 197 statistically significant differentially methylated CpGs
compared to normal, mapped to 152 genes.
To determine the biological processes enriched with the
differentially methylated genes, the 152 genes were uploaded
into the Ingenuity Pathway Analysis (IPA) tool. IPA integrates
genes and molecules that are part of the same biological functions or regulatory networks interacting together. The information used by IPA for gene integration comes from scientific and
review articles, textbooks, and HumanCyc metabolic pathways.
Keywords containing “keloid genes” were also applied to IPA.

TABLE II.
Top Network Functions Associated With Significantly
Differentiated Methylated Keloid Genes.
Associated Network Functions

IPA Score

Humoral immune response, protein synthesis,
cellular function, maintenance

35

Cellular movement, ophthalmic disease, cardiovascular system development, function
Developmental disorder, hereditary disorder,
neurological disease
Behavior, neurological disease, psychological
disorder

30

Developmental disorder, reproductive system
disease, cell cycle

25

28
25

IPA 5 Ingenuity Pathway Analysis.

Jones et al.: DNA Methylation Profiles in Keloids
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Fig. 1. Histidine degradation V1 pathway. This pathway is part of amino acid metabolism. In this pathway, L-histidine is catabolized/
degraded by distinct enzymes in mammalian liver and later degraded to N-formimino-L-glutamate. L-histidine is essential for immune
response, repair of wounds, and other natural repair mechanisms. Two genes from the keloid data set were among the 20 genes in this
pathway. Both of these genes were hypomethylated and predicted to be upregulated. [Color figure can be viewed in the online issue, which
is available at www.laryngoscope.com.]
This was accomplished using a query performed to call out gene
signaling and regulatory pathways of biological relevance in
keloid pathogenesis. The pathways (or “network”) with an
enrichment probability value  .01 were identified. These were
then subjected to a heuristic filter using a set of keywords
selected for their likely association with keloid. These keywords
were: fibroproliferative tumor, extracellular matrix, fibrogenesis,
keloid, fibroblast, collage, Kenalog, hypertrophic scar, inflammation, cheloid, cutaneous scar, dermal tumor, dermal fibroma,
overgrowth, hyperplasia, proliferation, fibrous tissue, extra collagen, darker skin pigmentation, keloid fibroblasts, benign tumors,
fibronectin, chondroitin sulfate, tumor growth factor beta (TGFb), proteoglycans, tissue repair, platelet-derived growth factor
alpha (PDGF-a) receptors, wound healing, cytokine production,
and glucose metabolism. Specifically, any pathway or network
with an annotation description that included one or more of the
keywords was retained. The goal of this analysis was to identify
and assess biological functions and signaling pathways/bionetworks associated with statistically significant molecules/genes
from methylation array analyses.

Statistical Analysis
Methylation beta ratios (keloid vs. normal) were converted
to fold change in IPA. Negative inverse (21/x) for values

Laryngoscope 127: January 2017

72

between 0 and 1 (e.g., 0.5 in ratio is 22 in fold change) and
values > 1 remained unchanged. A ratio of 22 represented a
2-fold change for a particular gene. Multiple CpG sites within a
gene were resolved by selection of the CpG with the highest
fold change ranking. Core analyses were done based on IPA
“genes only knowledge base,” with default parameters to
include validation options such as “experimentally validated”
and “highly predicted.” Expression value cutoff for analyses was
2 for both up- and downregulated genes. Pathways were considered enriched if the proportion of differentially methylated
genes present exceeded the proportion expected by chance based
upon a Fisher exact test.

RESULTS
Among 197 CpGs (including duplicates, as some of
the CpG sites were mapped to the same genes), 191
mapped to Ingenuity knowledge base. Six CpGs, without
mapped IDs in IPA, were excluded from analyses. In
analysis using IPA software, the 191 CpGs mapped to
152 unique keloid genes (see Supporting Table 1 in the
online version of this article). CpG ratios (keloid vs. normal) were converted to fold change in IPA.
Jones et al.: DNA Methylation Profiles in Keloids

Fig. 2. Colorectal cancer metastasis signaling. Six genes from the keloid gene list were enriched in this pathway. There are 258 genes in
total in this pathway. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]

Among the 152 unique genes, the top 10 hypermethylated genes were ACTR3C, LRRC61, PAQR4, C1orf109,
SLCO2B1, CMKLR1, AHDC1, FYCO1, CCDC34, and
CACNB2, and the top 10 hypomethylated genes were
GALNT3, SCML4, PPP1R13L, ANKRD11, WIPF1, MX2,
IFFO1, DENND1C, CFH, and GHDC.
The networks and pathway analysis were generated
through the use of QIAGEN’s Ingenuity Pathway AnalyR ,QIAGEN
sis (IPAV
Redwood City, www.qiagen.com/
ingenuity).
IPA identified nine associated pathways with keloid
gene/molecule enrichment probability values  0.01. Of
these, five pathways (histidine degradation V1, phospholipase C signaling, colorectal cancer metastasis signaling, P2Y purinergic receptor signaling pathway, and Gai
signaling) were associated with keloid-related keywords
and contained “keloid genes” with P < .05 (Table I). IPA
identified top biofunction networks that were generated
de novo based on keloid-specific data input based on a
score where a higher number of keloid genes represented higher significance (Table II). These networks
contain keloid genes that are in multiple pathways.

DISCUSSION
Keloids arise following injury to the dermis and are
commonly thought to result from abnormalities in normal
wound healing. Normally, these injuries proceed through
the four stages of wound healing (hemostasis, inflammation, proliferation, and remodeling). Keloids are fibroproliferative tumors thought to be an aberration in the
fundamental process of wound healing.5 In this study, the
histidine degradation pathway was the most statistically
significant pathway identified by IPA analysis (Table I,
Fig. 1). The histidine degradation pathway is integral to
amino acid metabolism. In this pathway, L-histidine is
catabolized/degraded by distinct enzymes in the mammaLaryngoscope 127: January 2017

lian liver and later degraded to N-formimino-Lglutamate. L-histidine is a semiessential amino acid that
is important for immune response and repair of
wounds.15,16 Two genes, AMDHD and MICAL3, from the
keloid data set were among the 20 genes that comprise
the histidine degradation pathway (Table I). These 2
genes were hypermethylated and predicted to be downregulated in keloids. The function of AMDHD and MICAL3
in keloid pathogenesis is unknown. MICAL3 is one of
three isoforms of the molecules interacting with CasL
(MICLA) protein found in humans, whose function is
thought to regulate actin microfilament regulation.17
Actin is a key component of myofibroblast function in
wound healing. Histidine is also responsible for histamine
synthesis.18 Histamine is involved in wound healing by
its effects on cell proliferation and migration, including
fibroblasts.19 Further study on alterations in the histidine
degradation pathway may lead to a better understanding
of how abnormalities in the wound healing process contribute to keloid formation.
Despite no reported cases of keloids crossing the
threshold to malignancy,14 associated keloid characteristics of hyperplasia and high recurrences are common
characteristics of tumorigenesis along a malignant continuum.8 Tumorigenesis occurs when the normal process
of cell division is altered in normal cells. Keloids are
benign proliferative tumors characterized by hyperplasia, recurrence, and the lack of progression to malignancy.
However,
keloids
display
malignantlike
phenotypes that spread beyond the original injury to
invade adjacent normal skin akin to cancer. Keloid
hyperplasia is thought to be due to a prolongation of the
proliferative phase of wound healing.20 This study has
identified epigenetic changes of keloid-specific methylated genes that have been implicated in the process of
tumorigenesis. The colorectal cancer metastasis signaling pathway, statistically significant in IPA analysis,
Jones et al.: DNA Methylation Profiles in Keloids
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Fig. 3. Ga signaling pathway. This pathway describes G-proteins as signaling molecules to a number of different types of ligands, including
neurotransmitters, hormones, and chemokines. Four of the keloid genes are among the 132 genes in this pathway. [Color figure can be
viewed in the online issue, which is available at www.laryngoscope.com.]

offers insight into keloid tumorigenesis (Fig. 2). Six
genes from the keloid list were among the 258 genes
located in this pathway (Table I). The colorectal cancer

metastasis signaling pathway features a number of
genetic instabilities, including microsatellite instability
and chromosome instability.21 These genetic instabilities

TABLE III.
Significantly Differentially Methylated Keloid Genes With Known Drug Targets in Ingenuity Pathway Analysis.
Gene Symbol

COL18A1
COMT

Entrez Gene Name

Fold Change

Location

Type(s)

Drug(s)

Collagen, type XVIII,
alpha 1

2.678

Extracellular space

Other

Collagenase clostridium
histolyticum

Catechol-Omethyltransferase

2.046

Cytoplasm

Enzyme

Carbidopa/entacapone/
levodopa, BIA-3-202,
tolcapone, entacapone
Ruxolitinib

JAK1

Janus kinase 1

22.086

Cytoplasm

Kinase

NOS1

Nitric oxide synthase 1
(neuronal)

22.191

Cytoplasm

Enzyme

GW 273629, omega-Nmethylarginine

P2RY12

Purinergic receptor
P2Y, G-protein
coupled, 12

2.139

Plasma membrane

G-protein coupled
receptor

Prasugrel, ticagrelor,
clopidogrel

THRA

Thyroid hormone
receptor, alpha

2.051

Nucleus

Ligand-dependent
nuclear receptor

3,5-Diiodothyropropionic acid,
amiodarone, levothyroxine,
L-triiodothyronine

TNK2

Tyrosine kinase,
nonreceptor, 2

2.006

Cytoplasm

Kinase

Vemurafenib

Laryngoscope 127: January 2017
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Fig. 4. Phospholipase C signaling pathway. This pathway is part of cell signaling pathways and vitamin and mineral metabolism. This pathway mainly describes different phospholipase families and their activation with G-proteins. Six genes from the keloid gene list were found
among the 260 total genes in this pathway. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]

mainly alter the Wnt, CdhE, prostaglandin, epidermal
growth factor receptor, TGF-b receptor, and DCC
(deleted in colorectal cancer) signaling routes to
facilitate tumorigenesis and colorectal carcinoma.21,22
The epigenetic alterations of genes in the Wnt signaling
pathway and its interaction with other pathways
have been implicated in tumor progression via both
proto-oncogene and tumor suppressor activity.23 Other
colorectal cancer metastasis signaling pathway alterations include TGF-b signaling, which is important in
wound healing24 and has been implicated in a number of
hyperproliferative diseases, including keloids.25,26 TGF-b
mediates both the excessive production of extracellular
Laryngoscope 127: January 2017

matrix and fibroblast proliferation as part of keloid
hyperplasia.27
The Gai signaling pathway describes G-proteins as
signaling molecules to a number of different types of
ligands such as neurotransmitters, hormones, and
chemokines (Fig. 3). Of the 132 genes in this pathway,
four are keloid genes (Table I). G-protein receptor
ligands have a pivotal role in many diseases, including
the activation of downstream regulators that stimulate
cancer progression and invasion.28 The activation of the
canonical Wnt pathway occurs through the binding of
Wnt ligands to the G-protein–coupled frizzled (FZD)
receptors.28 Inhibition of the Wnt/FZD coreceptor LRP6
Jones et al.: DNA Methylation Profiles in Keloids
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Fig. 5. P2Y purinergic receptor signaling pathway. This pathway describes receptors that are associated with specific functions like angiogenesis, neurotransmission, wound healing, morphogenesis, and apoptosis. There are four of the keloid genes among the 138 genes in this
pathway. [Color figure can be viewed in the online issue, which is available at www.laryngoscope.com.]

was associated with the repression of the Wnt pathway
as well as with cell proliferation in breast cancer.29
G-protein receptors and the Wnt signaling pathway
have been targets of anticancer therapeutic intervention
due to their roles in tumorigenesis.28,29 The elucidation
of these characteristics separately or collectively may
not only provide insight into keloid pathogenesis but
also shed light on the process of tumorigenesis along a
continuum to malignancy.
Further insight into the pathogenesis of keloids
can be found in the top hypomethylated and hypermethylated genes that were identified during pathway
analysis (see Supporting Table 1 in the online version
of this article). For example, C1ORF109, a gene that
was hypermethylated and suspected to be downregulated in this study, has been found to increase colony
number and cell proliferation in breast cancer cells due
to an increase in proliferation cell nuclear antigen and
cyclinD1 levels.30 Most of these genes have never been
Laryngoscope 127: January 2017
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implicated in keloid pathogenesis. Seven of these genes
already have drug targets that could serve as the basis
for new therapies (Table III). Table III shows the gene
name and symbol along with the production type and
location and the fold change difference between normal
and keloid tissue.
Apoptosis is important for controlling normal and
aberrant cell proliferation in wound healing and
tumorigenesis, respectively.31,32 PAQR4 was also hypermethylated and suspected to be downregulated. PQR4 is
a protein with multiple ligands, two of which are progestin and adipoQ. AdipoQ’s main function is to regulate
glucose metabolism and fatty acid oxidation. It also
counteracts the effects of TNF-a by inhibiting inflammatory response, and it interferes with apoptosis and subsequently may affect tumorigenesis.33 Similarly,
PPP1R13L (protein phosphatase 1, regulatory subunit
13 like), a top differentially methylated gene, plays a
role in regulating apoptosis via its ability to interact
Jones et al.: DNA Methylation Profiles in Keloids

with P53.34 Downregulation of p53 has been implicated
in the pathogenesis and aberrant growth of keloids.11,35
PPP1R13L was hypomethylated in this study, and its
altered gene expression could have a significant involvement in keloid pathogenesis.
ACTR3C, an actin-related protein, was a top gene
found to be hypermethylated by IPA analysis. Actinrelated proteins have been implicated in the suppression
of metastatic potential in lung adenocarcinoma.36
ACTR3C activity in keloids could help to explain why
there is no fibroblast invasion through the basement
membrane and no evidence of distant metastasis even
though keloids extend into adjacent normal tissue.
The phospholipase C (PLC) pathway was identified
as statistically significant in IPA analysis (Fig. 4). A
hypermethylated AHNAK was one of six differentially
methylated keloid genes among the 260 genes in this
pathway (Table II). AHNAK is an activator of the PLC
pathway. A review of the literature supports a role for
PLC-c in the secretion of matrix metalloproteinases
(MMPs).37,38 MMPs are a family of proteases whose
function includes the degradation of extracellular
matrix. MMP regulation has been implicated in keloid
pathogenesis because of a lack of extracellular matrix
degradation and has been associated with metastasis
due to degradation of the basement membrane.39–41
Alterations of ACTR3C and the PLC pathway could be
part of a common genetic profile that allows for tumorigenesis but stops short of transformation to malignancy
in keloids.
Pathway analysis also identified the P2Y purinergic
receptor signaling pathway as important in keloid pathogenesis (Fig. 5). There were four keloid genes among the
138 genes involved in this pathway (Table II). Purinergic
receptors are associated with specific functions like cell
proliferation, angiogenesis, neurotransmission, wound
healing, morphogenesis, and apoptosis.42,43 It remains to
be seen how alterations in the P2Y pathway may contribute to the pathogenesis of keloids given the importance of cell proliferation, angiogenesis, wound healing,
and apoptosis to keloid formation.

CONCLUSION
Although the roles of these genes in the pathogenesis of keloids have yet to be determined, their known
roles in the pathogenesis of other disease states could
lay the foundation for better understanding of keloid
tumorlike characteristics. This study places keloidspecific genes in known bionetwork pathways involved
in critical biological functioning and signaling events in
the cell. This information can be used to further refine
the screening process for biological significance in an
effort to better understand the pathogenesis and develop
molecular-targeted therapy for keloid disease.
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